ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional Results available

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

ClinicalTrials.gov ID: NCT03220022

Public ClinicalTrials.gov record NCT03220022. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

Study identification

NCT ID
NCT03220022
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
46 participants

Conditions and interventions

Interventions

  • Cyclophosphamide Drug
  • Doxorubicin Hydrochloride Drug
  • Etoposide Drug
  • Filgrastim Biological
  • Ibrutinib Drug
  • Laboratory Biomarker Analysis Other
  • Pegfilgrastim Biological
  • Pharmacological Study Other
  • Prednisone Drug
  • Rituximab Biological
  • Vincristine Sulfate Drug

Drug · Biological · Other

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 15, 2018
Primary completion
Oct 9, 2024
Completion
Jul 15, 2026
Last update posted
Apr 12, 2026

2018 – 2026

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
UC San Diego Moores Cancer Center La Jolla California 92093
UCSF Medical Center-Parnassus San Francisco California 94143
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136
Memorial Hospital West Pembroke Pines Florida 33028
John H Stroger Jr Hospital of Cook County Chicago Illinois 60612
University of Illinois College of Medicine - Chicago Chicago Illinois 60612
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287
Boston Medical Center Boston Massachusetts 02118
Siteman Cancer Center at Washington University St Louis Missouri 63110
Washington University School of Medicine St Louis Missouri 63110
Mount Sinai Hospital New York New York 10029
Memorial Sloan Kettering Cancer Center New York New York 10065
Montefiore Medical Center - Moses Campus The Bronx New York 10467
Memorial Sloan Kettering Nassau Uniondale New York 11553
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Pennsylvania Hospital Philadelphia Pennsylvania 19107
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Virginia Mason Medical Center Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03220022, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03220022 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →